Quantcast

Latest Brain tumor Stories

2014-07-24 16:24:49

Tony Danza Appointed as Master of Ceremonies for the Charitable Event NEW YORK, July 24, 2014 /PRNewswire-USNewswire/ -- Voices Against Brain Cancer, in partnership with New York Road Runners, will host its annual "Join The Voices! New York Run/Walk" on Sunday, August 10, 2014 at The Naumburg Bandshell in Central Park at 8:30 a.m. The charitable event, which last year raised close to one million dollars, will feature a five-mile run, a scenic walk, kids races and a fun family festival....

2014-07-22 12:30:35

BOSTON, July 22, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston with R&D in Lithuania, today announced it has received the CE Mark of approval for two novel neuromonitoring devices: the Vittamed 205 for non-invasive intracranial pressure (ICP) measurement and the Vittamed 505 for non-invasive Cerebrovascular autoregulation monitoring. "CE approval for both devices is not only an important milestone for our company as we move...

2014-07-15 08:28:10

Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order LUCERNE, Switzerland, July 15, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy. These physicians will now be able to treat recurrent glioblastoma...

2014-07-12 23:02:37

ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market. View All Therapeutic Area Market Research Reports at http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) July 12, 2014 “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive...

2014-07-11 23:09:19

Capital Institute for Neurosciences Begins Clinical Trial Delivering Chemotherapy Directly to Brain Tumors Starting with Incision in Leg Hopewell, NJ (PRWEB) July 11, 2014 The Capital Institute for Neurosciences at Capital Health today announced it has performed the first procedure in a clinical trial that delivers chemotherapy to brain tumors through a catheter inserted in the leg. During the procedure, done at Capital Health Medical Center – Hopewell, Dr. Erol Veznedaroglu, an...

2014-07-09 23:08:02

Renowned Experts Gather to Review Brain Tumor Cases, Give Inside Look into Tumor Board Experience Chicago, IL (PRWEB) July 09, 2014 With more than 120 types of brain tumors, there is no one-size-fits all approach to treatment. That is why in some instances, physicians engage the expertise of colleagues across specialties for discussion of a particular case. This multidisciplinary group is called a “tumor board” and is where these physicians can discuss each case to define the optimal...

2014-07-09 11:17:04

NIH/National Institute of Neurological Disorders and Stroke NIH-funded researchers find brain tumor cells disrupt the brain's protective barrier, offering potential avenues for therapy Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, a study in mice indicates. This finding could ultimately lead to new ways to bring about the death of the tumor, as therapies may be able to reach these...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-08 08:32:31

("Leading Edge" Gamma Knife Treatment, led by Christopher Duma, M.D., FACS and his team of researchers, offers hope to patients with Glioblastoma Multiforme) NEWPORT BEACH, Calif., July 8, 2014 /PRNewswire/ -- A study on the effects of an aggressive and strategic treatment called "Leading Edge" radiosurgery offers hope to patients diagnosed with life-threatening brain cancer. The study identifies the pathways of invasion of malignant glioma cells and provides a map in which a...

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related